Skip to main content
SpringerLink
Log in

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background

Ximelagatran, an oral direct thrombin inhibitor, is currently in clinical development for the prevention and treatment of thromboembolic disease. Following oral administration, ximelagatran undergoes rapid bioconversion to its active form, melagatran, via two minor intermediates. Obesity, defined as body mass index (BMI) >30 kg/m2, is a recognised risk factor for thrombosis. There is potential for differences in the pharmacokinetics and pharmacodynamics of drugs administered to obese versus non-obese patients, and some drugs may require alternative administration strategies in obese patients.

Objective

To investigate the effect of obesity on the pharmacokinetics and pharmacodynamics of melagatran after oral administration of ximelagatran.

Design and participants

This was an open-label, single-dose, group-matched study in which obese subjects (BMI 32–39 kg/m2; six male and six female; age 21–40 years) were matched by sex and age (±2 years) with non-obese subjects (BMI 21–26 kg/m2; six male and six female; aged 21–39 years). Each subject received a single oral dose of ximelagatran 24mg. Blood samples for determination of plasma concentrations of melagatran and activated partial thromboplastin times (APTT; a marker of melagatran pharmacodynamics) were collected up to 12 hours after administration.

Results

There were no statistically significant differences in the pharmacokinetic properties of melagatran between obese and non-obese subjects. Values of area under the melagatran plasma concentration-time curve, maximum plasma concentration (Cmax), time at which Cmax occurred and terminal elimination half-life were approximately 1 µmol · h/L, 0.2 µmol/L, 2 hours and 3 hours in both obese and non-obese subjects, respectively. In addition, there was no statistically significant difference between the obese and non-obese subjects in the amount of ximelagatran, melagatran or the minor intermediates ethyl-melagatran and melagatran hydroxyamidine excreted in urine. When relating the prolongation of APTT ratio to the square root of plasma concentration of melagatran and obesity status (no/yes), no statistically significant interaction between plasma concentration and obesity status was observed. Ximelagatran was well tolerated in both obese and non-obese subjects, and no bleeding events or serious adverse events occurred.

Conclusion

No differences in the pharmacokinetics or pharmacodynamics of melagatran were detected between obese and non-obese subjects after oral administration of ximelagatran, suggesting that dose adjustment of ximelagatran in obesity (BMI up to 39 kg/m2) is not necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Nordström M, Lindblad B, Bergqvist D, et al. A prospective study of the incidence of deep-vein thrombosis with a defined urban population. J Intern Med 1992; 232: 155–60

    Article  PubMed  Google Scholar 

  2. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism, The Worcester DVT study. Arch Intern Med 1991; 151: 933–8

    Article  PubMed  Google Scholar 

  3. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors, a focus on venous thrombosis. Thromb Haemost 1997; 78: 1–6

    PubMed  CAS  Google Scholar 

  4. Fenton JW, Ofosu FA, Brezniak DV, et al. Thrombin and antithrombotics. Semin Thromb Hemost 1998; 24: 87–91

    Article  PubMed  CAS  Google Scholar 

  5. Gustafsson D, Antonsson T, Bylund R, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79: 110–8

    PubMed  CAS  Google Scholar 

  6. Gustafsson D, Nyström J-E, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171–81

    Article  PubMed  CAS  Google Scholar 

  7. Eriksson UG, Bredberg U, Gislen K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharm. In press

  8. Eriksson UG, Bredberg U, Hoffman K-J, et al. Absorption, distribution, metabolism and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003; 31: 294–305

    Article  PubMed  CAS  Google Scholar 

  9. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215–21

    Article  PubMed  CAS  Google Scholar 

  10. Francis CW, Davidson BL, Berkowitz SD, et al. A randomized, double-blind, comparative study of ximelagatran and warfarin for the prevention of venous thromboembolism after total knee arthroplasty. Ann Intern Med 2002; 137: 648–55

    PubMed  CAS  Google Scholar 

  11. Eriksson BI, Lindbratt S, Kälebo P, et al. A randomised, controlled study of the oral direct thrombin inhibitor ximelagatran and its active form, melagatran, compared with dalteparin as thromboprophylaxis after total hip or total knee replacement: METHRO II. Lancet 2002; 360: 1441–7

    Article  PubMed  CAS  Google Scholar 

  12. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III study. Thromb Haemost 2003; 89(2): 288–96

    PubMed  CAS  Google Scholar 

  13. Eriksson H, Wåhlander K, Gustafsson D, et al. A randomised, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemostasis 2003; 1: 41–7

    Article  CAS  Google Scholar 

  14. Petersen P, SPORTIF II and IV Investigators. A long-term follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with atrial fibrillation [abstract 2953]. Blood 2001; 98 Suppl. 1: 706a

    Google Scholar 

  15. Seidell JC. Time trends in obesity: an epidemiological perspective. Horm Metab Res 1997; 29: 155–8

    Article  PubMed  CAS  Google Scholar 

  16. Cheymol G. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet 2000; 39: 215–31

    Article  PubMed  CAS  Google Scholar 

  17. Sanderink G-J, Liboux AL, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharm Ther 2002; 72: 308–18

    Article  CAS  Google Scholar 

  18. Larsson M, Logren U, Ahnoff M, et al. Determination of melagatran, a novel direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 2002; 766: 47–55

    Article  CAS  Google Scholar 

  19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41

    Article  PubMed  CAS  Google Scholar 

  20. Eriksson UG, Mandema JW, Karlsson MO, et al. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Clin Pharmacokinet. In press

Download references

Acknowledgements

This study was funded by AstraZeneca.The authors thank Dr Aideen Young for her valuable contributions to this manuscript.

Author information

Authors and Affiliations

  1. AstraZeneca LP, Wilmington, Delaware, USA

    Troy C. Sarich, Renli Teng, Gary R. Peters & Robert Homolka

  2. AstraZeneca R&D, Mölndal, Sweden

    Maria Wollbratt, Mia Svensson & Ulf G. Eriksson

Authors
  1. Troy C. Sarich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renli Teng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary R. Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Wollbratt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert Homolka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mia Svensson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ulf G. Eriksson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Troy C. Sarich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sarich, T.C., Teng, R., Peters, G.R. et al. No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran. Clin Pharmacokinet 42, 485–492 (2003). https://doi.org/10.2165/00003088-200342050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200342050-00006

Keywords

Search

Navigation